CNS Pharmaceuticals (CNSP) Other Non Operating Income (2023 - 2025)
CNS Pharmaceuticals' (CNSP) quarterly Other Non Operating Income came in at $35605.0 in Q4 2025, up 34.58% YoY from $26456.0 in Q4 2024, and down 3.83% on a QoQ basis from $37023.0 in Q3 2025.
CNS Pharmaceuticals (CNSP) Other Non Operating Income (2023 - 2025) Analysis & Trends
CNS Pharmaceuticals (CNSP) has 3 years of Other Non Operating Income data on file, last reported at $35605.0 in Q4 2025.
- Quarterly Other Non Operating Income rose 34.58% year-over-year to $35605.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $153785.0 (up 155.19% YoY) and the FY2025 annual result came in at $153785.0, up 155.19% from the prior year.
- Other Non Operating Income slipped to $35605.0 in Q4 2025, from $37023.0 in the prior quarter.
- In the past five years, Other Non Operating Income ranged from a high of $42548.0 in Q1 2025 to a low of $1845.0 in Q2 2024.
- A 3-year average of $21975.8 and a median of $25230.0 in 2024 frame the typical range for Other Non Operating Income.
- Annual changes were most pronounced in 2024 — Other Non Operating Income slumped 76.35% — and 2025, when it surged 1992.63%.
- Tracing CNSP's Other Non Operating Income over 3 years: stood at $7002.0 in 2023, then soared by 277.83% to $26456.0 in 2024, then soared by 34.58% to $35605.0 in 2025.
- The last three Other Non Operating Income figures came in at $35605.0 (Q4 2025), $37023.0 (Q3 2025), and $38609.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | CNS Pharmaceuticals | 2.65 Mn | -4.55 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 35,605.00 |
| Sep 30, 2025 | 37,023.00 |
| Jun 30, 2025 | 38,609.00 |
| Mar 31, 2025 | 42,548.00 |
| Dec 31, 2024 | 26,456.00 |
| Sep 30, 2024 | 25,230.00 |
| Jun 30, 2024 | 1,845.00 |
| Mar 31, 2024 | 6,731.00 |
| Dec 31, 2023 | 7,002.00 |
| Sep 30, 2023 | 12,883.00 |
| Jun 30, 2023 | 7,802.00 |